Ticker Hub
CADL — AI Analysis & Sentiment
5 recent AI-generated analyses for CADL. Sentiment and confidence insights updated continuously.
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Positive extended Phase 3 clinical data for CAN-2409 significantly de-risks the drug's path to market and strengthens Candel Therapeutics' long-ter...
May 15, 2026Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
This strategic commercialization agreement positions Candel Therapeutics for potential future revenue from its lead prostate cancer drug upon regul...
Apr 29, 2026Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics reported positive extended survival data for its lead drug candidate, CAN-2409, in advanced non-small cell lung cancer. This pr...
Mar 17, 2026Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics has significantly bolstered its financial standing with over $200 million in new capital, providing a runway to Q1 2028. This c...
Mar 12, 2026Candel Therapeutics Announces Proposed $100 Million Public Offering
Candel Therapeutics' proposed $100M stock offering, while securing funding for crucial clinical trials, will cause substantial dilution to existing...
Feb 19, 2026